Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Brian Matthew Wolpin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0455-1032; OpenAlex author ID A5024348036, A5047496278, A5135284299; NIH RePORTER profile ID 9631396. Sources: ClinicalTrials.gov.

Their work

Papers
156 (first author 11, last author 36)
Trials
3 (principal investigator on 3)
Grants
5
Labs led
1
Collaborators
508
Papers, trials and grants by year

2011: 1 paper, 1 trial · 2012: 4 papers, 1 trial · 2013: 10 papers, 1 grant · 2014: 7 papers · 2015: 6 papers · 2016: 8 papers · 2017: 9 papers · 2018: 10 papers · 2019: 8 papers · 2020: 15 papers · 2021: 18 papers · 2022: 7 papers · 2023: 15 papers, 1 grant · 2024: 10 papers · 2025: 7 papers · 2026: 21 papers, 2 grants

Papers 50 of 156

  1. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70573↗
  2. Adherence to the Mediterranean diet and risk of pancreatic cancer: an analysis of 2.3 million participants in the Pooling Project of Prospective Studies of Die… Co-author DOI 10.1007/s10654-026-01418-x↗
  3. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  4. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  5. GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117314↗
  6. Risk of Pancreatic Cancer Associated With Precursor Lesions in Individuals and First-Degree Relatives: A Nationwide Cohort Study. Co-author DOI 10.1016/j.cgh.2026.06.009↗
  7. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗
  8. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Last author DOI 10.1038/s43018-026-01165-8↗
  9. Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. First author DOI 10.1056/nejmc2611022↗
  10. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2505783↗
  11. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Last author DOI 10.1056/nejmoa2605555↗
  12. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  13. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  14. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Co-author DOI 10.1158/1078-0432.ccr-25-4061↗
  15. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  16. Pancreatic cancer-associated organ dysfunction promotes muscle autophagy and contributes to peripheral tissue wasting Co-author DOI 10.64898/2026.02.27.708635↗
  17. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  18. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  19. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  20. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  21. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adeno… Co-author DOI 10.64898/2026.10.05.756824↗
  22. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  23. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Co-author DOI 10.1126/science.adk3487↗
  24. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  25. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  26. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  27. Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America. Co-author DOI 10.1371/journal.pmed.1004590↗
  28. Resistance exercise combined with protein supplementation for skeletal muscle mass in people with pancreatic cancer undergoing neoadjuvant chemotherapy: Study … Co-author DOI 10.1371/journal.pone.0322192↗
  29. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  30. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  31. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  32. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Last author DOI 10.1136/gutjnl-2023-331074↗
  33. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  34. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  35. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  36. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  37. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0873↗
  38. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  39. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
  40. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Co-author DOI 10.1016/j.xcrm.2023.101007↗
  41. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  42. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. Last author DOI 10.1038/s41467-023-38088-2↗
  43. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Last author DOI 10.1038/s41467-023-40024-3↗
  44. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Co-author DOI 10.1038/s41591-023-02332-5↗
  45. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Last author DOI 10.1093/oncolo/oyad002↗
  46. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
  47. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Last author DOI 10.1158/0008-5472.can-22-3050↗
  48. Relationship between ABO Blood Group Alleles and Pancreatic Cancer Is Modulated by Secretor (FUT2) Genotype, but Not Lewis Antigen (FUT3) Genotype. Co-author DOI 10.1158/1055-9965.epi-23-0009↗
  49. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  50. Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival. Last author DOI 10.1158/1055-9965.epi-23-0505↗

Trials 3

  1. Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer Principal investigator NCT01473303↗
  2. Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer Principal investigator NCT01273805↗
  3. OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas Principal investigator NCT01600807↗

Grants 5

  1. FY2026 Lustgarten grant: Brian Wolpin; Andrew Aguirre; Julie Sutcliffe AWARD lustgarten:2026-brian-wolpin-andrew-aguirre-julie-sutcli-fy2026-lustgarten-grant-brian-wolpin-and
  2. Altered metabolism and machine learning for pancreatic cancer early detection U01CA210171↗
  3. Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma P50CA127003↗
  4. Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer K07CA140790↗
  5. Lustgarten Laboratory at Dana-Farber Cancer Institute AWARD lustgarten:na-brian-wolpin-lustgarten-laboratory-at-dana-farber-can

Closest collaborators

The 25 strongest of 508 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan Andrew Nowak · 37 shared papers, 2017–2026 · strength 4.62
  2. Andrew J. Aguirre · 33 shared papers, 2018–2026 · strength 4.39
  3. Kimberly J. Perez · 29 shared papers, 2017–2026 · strength 3.96
  4. Chen Yuan · 38 shared papers, 2013–2026 · strength 3.66
  5. Michael Hayden Rosenthal · 17 shared papers, 1 shared grant, 2017–2026 · strength 3.48
  6. Douglas Adam Rubinson · 35 shared papers, 2013–2026 · strength 3.41
  7. Kimmie Ng · 38 shared papers, 2012–2026 · strength 3.30
  8. James M. Cleary · 22 shared papers, 2014–2026 · strength 3.11
  9. Charles S. Fuchs · 38 shared papers, 1 shared grant, 2011–2023 · strength 2.85
  10. Harshabad Singh · 18 shared papers, 2021–2026 · strength 2.74
  11. Ana Babić · 29 shared papers, 2016–2024 · strength 2.47
  12. Thomas E. Clancy · 21 shared papers, 2015–2026 · strength 2.12
  13. Peter Kraft · 27 shared papers, 2012–2023 · strength 1.96
  14. Andressa Dias Costa · 16 shared papers, 2019–2026 · strength 1.93
  15. Srivatsan Raghavan · 14 shared papers, 2018–2026 · strength 1.83
  16. Brandon M. Huffman · 11 shared papers, 2021–2026 · strength 1.73
  17. Edward L. Giovannucci · 27 shared papers, 2011–2023 · strength 1.69
  18. Matthew B.B. Yurgelun · 12 shared papers, 2019–2026 · strength 1.68
  19. Eileen Mary O'Reilly · 10 shared papers, 2013–2026 · strength 1.60
  20. Qiao-Li Wang · 9 shared papers, 2022–2026 · strength 1.49
  21. Vicente Morales‐Oyarvide · 21 shared papers, 2016–2023 · strength 1.47
  22. Joseph Douglas Mancias · 9 shared papers, 2017–2026 · strength 1.31
  23. Thomas Adam Abrams · 10 shared papers, 2012–2026 · strength 1.21
  24. Stephanie K. Dougan · 8 shared papers, 2021–2026 · strength 1.20
  25. Natalia I. Khalaf · 14 shared papers, 2017–2023 · strength 1.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.